By Fineline Cube 
China’s Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced the signing of a strategic cooperation agreement with Cutia Therapeutic (HKG: 2487). The partnership will focus on the import and general distribution of Codon Biopharma’s innovative drugs “Finasteride Spray” and “Minocycline Hydrochloride Foam” across mainland China.
Collaboration Details
Under the agreement, SPH will provide comprehensive support to Cutia Therapeutic. This includes bonded import services, nationwide distribution, supply chain optimization, and innovative value-added services. These efforts aim to accelerate the commercialization of Codon Biopharma’s innovative products.
Commercialization Strategy
The collaboration between SPH and Cutia Therapeutic is expected to leverage the strengths of both companies. By combining SPH’s extensive distribution network and supply chain expertise with Cutia’s innovative drug portfolio, the partnership is poised to enhance market penetration and accessibility for Codon Biopharma’s products.-Fineline Info & Tech